Viridian Therapeutics Inc [VRDN] stock prices are up 20.67% to $21.54 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The VRDN shares have gain 10.29% over the last week, with a monthly amount drifted -0.46%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Needham reaffirmed its Buy rating on September 11, 2024, and elevated its price target to $38. On June 11, 2024, Wolfe Research initiated with a Outperform rating and assigned a price target of $29 on the stock. Goldman started tracking the stock assigning a Buy rating and suggested a price target of $23 on June 06, 2024. Ladenburg Thalmann downgraded its rating to a Neutral. B. Riley Securities downgraded its rating to Neutral for this stock on May 09, 2024, and downed its price target to $20.
The stock price of Viridian Therapeutics Inc [VRDN] has been fluctuating between $11.40 and $27.20 over the past year. Currently, Wall Street analysts expect the stock to reach $22.75 within the next 12 months. Viridian Therapeutics Inc [NASDAQ: VRDN] shares were valued at $21.54 at the most recent close of the market. An investor can expect a potential return of 5.62% based on the average VRDN price forecast.
Analyzing the VRDN fundamentals
The Viridian Therapeutics Inc [NASDAQ:VRDN] reported sales of 0.30M for trailing twelve months, representing a surge of 19.44%. Gross Profit Margin for this corporation currently stands at -20.48% with Operating Profit Margin at -937.23%, Pretax Profit Margin comes in at -851.27%, and Net Profit Margin reading is -851.27%. To continue investigating profitability, this company’s Return on Assets is posted at -0.33, Equity is -0.45 and Total Capital is -0.39. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 20.44 points at the first support level, and at 19.35 for the second support level. However, for the 1st resistance point, the stock is sitting at 23.14, and for the 2nd resistance point, it is at 24.75.
Ratios To Look Out For
It’s worth pointing out that Viridian Therapeutics Inc [NASDAQ:VRDN]’s Current Ratio is 18.55. Also, the Quick Ratio is 18.55, while the Cash Ratio stands at 4.84. Considering the valuation of this stock, the price to sales ratio is 5643.22, the price to book ratio is 3.29.
Transactions by insiders
Recent insider trading involved Beetham Thomas W., Chief Operating Officer, that happened on Sep 27 ’24 when 5000.0 shares were purchased. President and CEO, Mahoney Stephen F. completed a deal on Sep 27 ’24 to buy 21400.0 shares. Meanwhile, Director Fairmount Funds Management LLC bought 1.6 million shares on Sep 13 ’24.
